Zebrafish as a preclinical in vivo screening model for nanomedicines
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
The interactions of nanomedicines with biological environments is heavily influenced by their physicochemical properties. Formulation design and optimization are therefore key steps towards successful nanomedicine development. Unfortunately, detailed assessment of nanomedicine formulations, at a macromolecular level, in rodents is severely limited by the restricted imaging possibilities within these animals. Moreover, rodent in vivo studies are time consuming and expensive, limiting the number of formulations that can be practically assessed in any one study. Consequently, screening and optimisation of nanomedicine formulations is most commonly performed in surrogate biological model systems, such as human-derived cell cultures. However, despite the time and cost advantages of classical in vitro models, these artificial systems fail to reflect and mimic the complex biological situation a nanomedicine will encounter in vivo. This has acutely hampered the selection of potentially successful nanomedicines for subsequent rodent in vivo studies. Recently, zebrafish have emerged as a promising in vivo model, within nanomedicine development pipelines, by offering opportunities to quickly screen nanomedicines under in vivo conditions and in a cost-effective manner so as to bridge the current gap between in vitro and rodent studies. In this review, we outline several advantageous features of the zebrafish model, such as biological conservation, imaging modalities, availability of genetic tools and disease models, as well as their various applications in nanomedicine development. Critical experimental parameters are discussed and the most beneficial applications of the zebrafish model, in the context of nanomedicine development, are highlighted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stages of embryonic development of the zebrafish
Kimmel, C. B., Ballard, W. W., Kimmel, S. R., Ullmann, B., & Schilling, T. F. (1995) · Developmental Dynamics · doi:10.1002/aja.1002030302 · Cited by 12,037
Stimuli-responsive nanocarriers for drug delivery
Mura, S., Nicolas, J., & Couvreur, P. (2013) · Nature Materials · doi:10.1038/nmat3776 · Cited by 6,289
MANTOVANI, A., SOZZANI, S., LOCATI, M., ALLAVENA, P., & SICA, A. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(02)02302-5 · Cited by 5,528
The zebrafish reference genome sequence and its relationship to the human genome.
Howe, K., Clark, M. D., Torroja, C. F., Torrance, J., Berthelot, C., Muffato, M., Collins, J. E., Humphray, S., McLaren, K., Matthews, L., et al. (2013) · Nature · doi:10.1038/nature12111 · Cited by 5,100
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
Adams, D., Gonzalez-Duarte, A., O’Riordan, W. D., Yang, C.-C., Ueda, M., Kristen, A. V., Tournev, I., Schmidt, H. H., Coelho, T., Berk, J. L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716153 · Cited by 3,047
Toxicity of cationic lipids and cationic polymers in gene delivery
Lv, H., Zhang, S., Wang, B., Cui, S., & Yan, J. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.04.014 · Cited by 2,286
Aggarwal, P., Hall, J. B., McLeland, C. B., Dobrovolskaia, M. A., & McNeil, S. E. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.03.009 · Cited by 1,791
Transparent Adult Zebrafish as a Tool for In Vivo Transplantation Analysis
White, R. M., Sessa, A., Burke, C., Bowman, T., LeBlanc, J., Ceol, C., Bourque, C., Dovey, M., Goessling, W., Burns, C. E., et al. (2008) · Cell Stem Cell · doi:10.1016/j.stem.2007.11.002 · Cited by 1,408
Danhier, F. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.11.015 · Cited by 1,288
Lipid Nanoparticle Systems for Enabling Gene Therapies
Cullis, P. R., & Hope, M. J. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.013 · Cited by 1,208
3D Cell Culture Systems: Advantages and Applications
Ravi, M., Paramesh, V., Kaviya, S. R., Anuradha, E., & Solomon, F. D. P. (2015) · Journal of Cellular Physiology · doi:10.1002/jcp.24683 · Cited by 1,206
Organs-on-chips at the frontiers of drug discovery
Esch, E. W., Bahinski, A., & Huh, D. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4539 · Cited by 1,185
Bertrand, N., Grenier, P., Mahmoudi, M., Lima, E. M., Appel, E. A., Dormont, F., Lim, J.-M., Karnik, R., Langer, R., & Farokhzad, O. C. (2017) · Nature Communications · doi:10.1038/s41467-017-00600-w · Cited by 708
Lipid nanoparticles enabling gene therapies: from concepts to clinical utility
Kulkarni, J. A., Cullis, P. R., & van der Meel, R. (2018) · Nucleic Acid Therapeutics · doi:10.1089/nat.2018.0721 · Cited by 592
Microfluidic 3D cell culture: from tools to tissue models
van Duinen, V., Trietsch, S. J., Joore, J., Vulto, P., & Hankemeier, T. (2015) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2015.05.002 · Cited by 500
Biological Identity of Nanoparticles In Vivo : Clinical Implications of the Protein Corona
Caracciolo, G., Farokhzad, O. C., & Mahmoudi, M. (2017) · Trends in Biotechnology · doi:10.1016/j.tibtech.2016.08.011 · Cited by 426
Hadjidemetriou, M., Al-Ahmady, Z., Mazza, M., Collins, R. F., Dawson, K., & Kostarelos, K. (2015) · ACS Nano · doi:10.1021/acsnano.5b03300 · Cited by 358
Karlsson, J., von Hofsten, J., & Olsson, P.-E. (2001) · Marine Biotechnology · doi:10.1007/s1012601-0053-4 · Cited by 328
Effects of RAS on the genesis of embryonal rhabdomyosarcoma
Langenau, D. M., Keefe, M. D., Storer, N. Y., Guyon, J. R., Kutok, J. L., Le, X., Goessling, W., Neuberg, D. S., Kunkel, L. M., & Zon, L. I. (2007) · Genes & Development · doi:10.1101/gad.1545007 · Cited by 320
Translational value of mouse models in oncology drug development
Gould, S. E., Junttila, M. R., & de Sauvage, F. J. (2015) · Nature Medicine · doi:10.1038/nm.3853 · Cited by 293
Paunovska, K., Sago, C. D., Monaco, C. M., Hudson, W. H., Castro, M. G., Rudoltz, T. G., Kalathoor, S., Vanover, D. A., Santangelo, P. J., Ahmed, R., et al. (2018) · Nano Letters · doi:10.1021/acs.nanolett.8b00432 · Cited by 277
Cancer-on-a-chip systems at the frontier of nanomedicine
Zhang, Y. S., Zhang, Y.-N., & Zhang, W. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.03.011 · Cited by 127
Løvmo, S. D., Speth, M. T., Repnik, U., Koppang, E. O., Griffiths, G. W., & Hildahl, J. P. (2017) · Developmental & Comparative Immunology · doi:10.1016/j.dci.2016.06.016 · Cited by 41
Cited by
Current hurdles to the translation of nanomedicines from bench to the clinic
Đorđević, S., Gonzalez, M. M., Conejos-Sánchez, I., Carreira, B., Pozzi, S., Acúrcio, R. C., Satchi-Fainaro, R., Florindo, H. F., & Vicent, M. J. (2022) · Drug Delivery and Translational Research · doi:10.1007/s13346-021-01024-2 · Cited by 657
Lipid-Based DNA Therapeutics: Hallmarks of Non-Viral Gene Delivery
Buck, J., Grossen, P., Cullis, P. R., Huwyler, J., & Witzigmann, D. (2019) · ACS Nano · doi:10.1021/acsnano.8b07858 · Cited by 312
Self-citationAnionic Lipid Nanoparticles Preferentially Deliver mRNA to the Hepatic Reticuloendothelial System
Pattipeiluhu, R., Arias‐Alpizar, G., Basha, G., Chan, K. Y. T., Bussmann, J., Sharp, T. H., Moradi, M., Sommerdijk, N., Harris, E. N., Cullis, P. R., et al. (2022) · Advanced Materials · doi:10.1002/adma.202201095 · Cited by 194
Self-citationCardiovascular toxicity assessment of polyethylene nanoplastics on developing zebrafish embryos
Sun, M., Ding, R., Ma, Y., Sun, Q., Ren, X., Sun, Z., & Duan, J. (2021) · Chemosphere · doi:10.1016/j.chemosphere.2021.131124 · Cited by 164
Intravital microscopy for real-time monitoring of drug delivery and nanobiological processes
Momoh, J., Kapsokalyvas, D., Vogt, M., Hak, S., Kiessling, F., van Zandvoort, M., Lammers, T., & Sofias, A. M. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114528 · Cited by 33
Metadata
- Authors
- Sieber, S., Grossen, P., Bussmann, J., Campbell, F., Kros, A., Witzigmann, D., & Huwyler, J.
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2019-11
- Volume
- 151-152
- Pages
- 152-168
- ISSN
- 0169-409X (ISSN-L)
- OpenAlex
- W2907368812
- Cited by
- 152
- References
- 23
- FWCI
- 2.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.